# Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

> **NCT00148772** · PHASE2 · COMPLETED · sponsor: **Endeavor Health** · enrollment: 29 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Erlotinib (Tarceva)

## Key facts

- **NCT ID:** NCT00148772
- **Lead sponsor:** Endeavor Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2011-06-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148772, "Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00148772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*